"I targeted several CNS disease areas and researched companies with late-stage clinical developments to look for good investment candidates. I explored Huntington's disease, Epilepsy, ALS, Alzheimer's, and depression, researching an average of 10 companies per disease and completing comparative drug analyses to determine which companies have the highest probability of success. I also completed a few case studies and made recommendations for two companies which led to actual investments (and eliminated several other companies as investment candidates, which is also useful). Critically reading papers, using statistics principles to interpret data, and employing biotechnology literacy were all essential to my job and skills which I developed at MIT. I also became familiar with a wide range of upcoming technologies in the biotech sector and a range of diseases. I think my business trip to Zurich was the most memorable thing I experienced, where I got to meet with the CEO of a cutting-edge biotech company."